^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DPX-E7

    i
    Other names: DPX-E7, DPX E7, HPV16-E711-19
    Associations

    News

    Trials
    Company:
    BioVaxys
    Drug class:
    HPV-16 E7 protein inhibitor, Viral protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
    P1/2, N=11, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Feb 2023
    Trial completion • Trial completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A2 positive
    |
    cyclophosphamide • DPX-E7
    almost3years
    Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A2 positive
    |
    DPX-E7
    over3years
    Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A2 positive • HLA-A*02 positive
    |
    DPX-E7